Nabriva Therapeutics — Q3 2019 Earnings Presentation
27 slides from Nabriva Therapeutics's earnings presentation, Nov 12, 2019
Slide 1: Safe Harbor and Disclaimer
Safe Harbor and Disclaimer This presentation contains forward-looking statements about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about launch and commercialization of XENLETA for the treatment of CABP, the development of CONTEPO for cU
Slide 2: Nabriva Q3 2019 Earnings Call: Agenda
3 Nabriva Q3 2019 Earnings Call: Agenda 3rd Quarter Overview & Business Update Ted Schroeder, Chief Executive Officer Commercial Highlights Francesco Maria Lavino, Chief Commercial Officer Financial Review Gary Sender, Chief Financial Officer Closing Remarks and Q&A Ted Schroeder, Chief Executive Of
Slide 3: 3rd Quarter Business Update
3rd Quarter Business Update Ted Schroeder, Chief Executive Officer
Slide 4: Nabriva in 2019: A Transformative Year
Nabriva in 2019: A Transformative Year Strengthened balance sheet and extended cash runway into Q3 20 * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.
Slide 5: XENLETA Launch Highlights
XENLETA Launch Highlights Executing on our 90 Day Plan to Build a Solid Foundation for a Successful Launch Significant Interest and Uptake in Hospitals XenletaTM (lefamulin) launched in the US on September 9th, just 3 weeks after approval Nabriva Sales Force has called on all 900 target hospitals* (
Slide 6: Nabriva in 2019: A Transformative Year
Nabriva in 2019: A Transformative Year Strengthened balance sheet and extended cash runway into Q3 20 * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.
Slide 7: Pneumonia: A Leading Cause of Morbidity, Mortality, and Healthcare Cost
Pneumonia A Leading Cause of Morbidity, Mortality, and Healthcare Cost #3 Cause of hospital readmission6 ~5MM Cases Annually in US1 #5 Cause of total hospitalizations7 #1 Cause of infectious death5 Mortality rate ~$17B ~15% in hospital8 ~25 – 30% in ICU9,10 Direct costs of pneumonia11 8 Distribution
Slide 8: Commercial Highlights
Commercial Highlights Francesco Maria Lavino, CCO 9
Slide 9: XENLETA Commercial Strategy: Three Distinct Opportunities for CABP
Outpatients Transition of Care In-Patients Prioritized Accounts Community Hospital Point of Care: Initial Nabriva Focus 1 2 3 A: Healthcare Cost and Utilization Project (HCUP) 2013, Age 18+ (projected to 2029) B: Community Data (CDC 2009-2010), Age 18+ (projected to 2029) C: Company Sponsored Market
Slide 10: Pull Through Supporting a Successful Launch
Pull Through Supporting a Successful Launch Supporting the Transition of Care Strategy Ensure HUB Service in place to enable effective discharge 1 2 Ensure XENLETA Sales Force connects with prioritized accounts to accelerate Formulary Placement & Transition of Care 3 Ensure XENLETA is scheduled for
Slide 11: XENLETA Launch: Availability and Initial Orders
September 9th XENLETA launch 3 weeks after approval Specialty distributors have adequate inventory ASD, Cardinal Specialty and McKesson Specialty Walgreens Community Specialty Pharmacy and Option Care Health Initial orders include hospitals & specialty pharmacies >200 orders for XENLETA from Hospita
Slide 12: Experienced Territory Business Managers Launching XENLETA
2 13 60 highly experienced, Territory Business Managers (TBMs) launching XENLETA 100% have in depth hospital experience (average of 14.5 years) 75% have ID experience (average of 9.5 years) Hospital experience includes ED, ICU, Cardiac-Cath/Procedure Areas To date, TBMs have connected with all 900 T
Slide 13: Hospital Formulary Access
3 14 >200 hospital accounts plan to review XENLETA by Dec 31st >400 total hospital accounts expected to review XENLETA by end of Q1 20 Majority of hospitals pending review by end of Q1 20 are large systems or Nabriva priority accounts Trend indicates higher hospital access within 6 months, compared
Slide 14: Managed Care Access
4 15 Majority of clinical reviews in first 90 days ~ 150MM (49%) of covered lives have access; majority with no utilization management (PA/ST) ~ 45MM Commercial and Medicare Part D lives under contract, ~90% with no utilization management In process of contracting with all Commercial and Medicare Pa
Slide 15: XENLETA Opportunity for Increased Reimbursement in the Transition of Care
XENLETA Opportunity for Increased Reimbursement in the Transition of Care 16 XENLETA IV has been granted a C Code C9054 (Pass Through Status), effective on Jan 1, 2020 Will allow Outpatient departments to bill Medicare at ASP + 6% for XENLETA IV XENLETA’s J Code Application expected to be submitted
Slide 16: XENLETA Launch Near Term Priority
XENLETA Launch Near Term Priority Continue to finalize Medicare and Commercial contracts to further expand XENLETA access Continue to work with Key Hospital Accounts to help secure P&T Review of XENLETA Drive Initial Purchase and Utilization at High Priority Accounts, Prior to Formulary Review Pull
Slide 17: The Focused Effort in the Community
The Focused Effort in the Community Targeted outreach designed to leverage existing hospital sales force to begin accessing the 2.3MM CABP outpatients A substantial opportunity that differentiates XENLETA from other recent antibiotic launches Targeting visits to over 6,000 community HCPs who are: Wi
Slide 18: Financial Review
Financial Review Gary Sender, CFO 19
Slide 19: Q3 – Finance Highlights
Q3 19 – Finance Highlights XenletaTM (lefamulin) launched on September 9th in the US - just 3 weeks after approval Net sales of $1.4MM in the first 3 weeks on the US Market, exceeding 2019 expectations Cash & short term investments = $78.3 MM on September 30th, higher than Q2 19 ending balance Signi
Slide 20: Income Statement – Q3 19 versus Q3 18
Three Months Ended, September 30, Change (in thousands) 2018 2019 3 months Revenues Product revenue, net $ 0 $ 1,445 $ 1,445 Collaboration revenue 0 5,051 5,051 Research premium and grant income 461 424 (37) Operating expenses Cost of revenue – product sales 0 (15) (15) Research and development (40,
Slide 21: Q3 Balance Sheet
Q3 19 Balance Sheet (in thousands) As of December 31, 2018 As of September 30, 2019 Current assets Cash and cash equivalents $ 102,003 $ 78,101 Restricted cash 0 228 Short-term investments 225 175 Accounts receivable 3,871 6,540 Contract Asset 1,500 - Inventory - 162 Prepaid expenses 1,154 1,202 108
Slide 22: Closing Remarks and Q&A
Closing Remarks and Q&A Ted Schroeder, CEO 23
Slide 23: XENLETA: Strongly Positioned for a Successful Launch
XENLETA: Strongly Positioned for a Successful Launch XENLETA offers a new, differentiated mechanism of action, with a complete spectrum of coverage of main CABP pathogens, including MDR strains, in a well tolerated short course of IV and Oral monotherapy Highly experienced and talented HQ and field
Slide 24: XENLETA: Strongly Positioned for a Successful Launch
XENLETA: Strongly Positioned for a Successful ~~ XENLETA offers a new, differentiated mechanism of action, with a complete spectrum of coverage of main CABP pathogens, including MDR strains, in a well tolerated short course of IV and Oral monotherapy Highly experienced and talented HQ and field team
Slide 25: Appendix
Appendix 26
Slide 26: References to Slide
References to Slide 8 MIC=minimum inhibitory concentration. *Data presented are from 2010 to September 2019. Dataset provided by JMI Labs and the SENTRY Antimicrobial Surveillance Program. sentry-mvp.jmilabs.com. Accessed October 5, 2019. 1. National Ambulatory Medical Care Survey (NAMCS) and Nation
Slide 27: References to Slide
References to Slide 8 Distribution of axithromycin, ampiclin, and doxycycline resistance for . pneumonize across the US** Micsminimum inhibitory concentration. ‘bata presented are from 2010 to September 2019, Dataset provided by JMI Labs and the SENTRY Antimicrobial Surveillance Program, sentry-mvp